NCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04634552 2026-04-13
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05552222 2026-04-13
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06285318 2026-04-13
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT06500884 2026-04-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07032714 2026-04-13
MAGENTA
Massachusetts General Hospital
Phase 1 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT06066346 2026-03-04
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05972135 2026-02-23
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT06100237 2026-02-23
REVIVE
University of Miami
Phase 2 Recruiting